NMPA

$10+ Billion Acne Medication Markets by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel - Global Opportunity Analysis and Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022

The "Acne Medication Market by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acne Medication Market by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Hence, there is huge demand for topical as well as oral acne medication.
  • On the other hand, oral acne medication is relatively more effective where moderate to severe acne do not respond to topical agents.
  • Numerous factors such as changing hormone levels, rising teenage population, and growing adoption of skincare products significantly drive the growth of global acne medication market.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

Retrieved on: 
Friday, September 30, 2022

Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.

Key Points: 
  • Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.
  • Vivoryon presented detailed safety data from the VIVIAD study at the Alzheimers Association International Conference (AAIC) in San Diego (July 31 to August 4, 2022).
  • On June 22, 2022, Vivoryon held its Annual General Meeting where all voting items were approved with a large majority.
  • Condensed Statements of Profit or Loss and Other Comprehensive Income for the six months ended June 30, 2022 and 2021

AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million

Retrieved on: 
Tuesday, September 27, 2022

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Key Points: 
  • This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance.
  • These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

KiOmed Pharma and Hansoh Pharma Announce License Agreement for KiOmedinevsOne in China’s Mainland, Macau and Taiwan

Retrieved on: 
Monday, September 26, 2022

Hansoh will receive exclusive rights to develop and commercialize KiOmedinevsOne and its future extensions in the territory.

Key Points: 
  • Hansoh will receive exclusive rights to develop and commercialize KiOmedinevsOne and its future extensions in the territory.
  • KiOmed retains the right to develop and commercialize KiOmedinevsOne in all other global markets.
  • We are very excited to partner with Hansoh Pharma, one of the largest biopharmaceutical entities in Greater China.
  • We are very glad to see KiOmeds product (KiOmedinevsOne) will help to solve this problem, said Eliza Sun, Executive Director of the Board of Hansoh Pharma.

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

A Taste of Ginger Returns for Successful Gathering with CSOFT CEO Shunee Yee as Co-Chair, Bringing Focus to Patient Diversity in Diabetes Care

Retrieved on: 
Thursday, September 22, 2022

BOSTON, Sept. 22, 2022 /PRNewswire-PRWeb/ -- CSOFT Health Sciences, leaders in medical translations, are pleased to announce a successful gathering for the 17th annual A Taste of Ginger on September 19th with CSOFT founder and CEO Shunee Yee as event Co-Chair, marking the event's first return to in-person gathering following the pandemic.

Key Points: 
  • BOSTON, Sept. 22, 2022 /PRNewswire-PRWeb/ -- CSOFT Health Sciences, leaders in medical translations, are pleased to announce a successful gathering for the 17th annual A Taste of Ginger on September 19th with CSOFT founder and CEO Shunee Yee as event Co-Chair, marking the event's first return to in-person gathering following the pandemic.
  • Hosted by Harvard University's Joslin Diabetes Center and the Asian American Diabetes Initiative (AADI), A Taste of Ginger is a culinary fundraising event dedicated to addressing the disproportionate impact of diabetes among Asian American demographics.
  • "A Taste of Ginger is an important opportunity to focus for the underrepresentation of Asian Americans in clinical trials for conditions that disproportionately affect this demographic.
  • CSOFT's operations are certified in ISO 17100:2015, ISO 9001:2015, and ISO 13485:2016, ensuring customized solutions meet the rigorous regulatory requirements of global submissions.

PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

Retrieved on: 
Thursday, September 22, 2022

The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs.

Key Points: 
  • The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs.
  • The extended blood sample stability enables easy centralization of sample processing, which expands access to the T-SPOT.TB test and gives laboratories more flexibility with the potential for sample batching.
  • Automation closes the gap between ELISPOT and ELISA laboratory workflows, enabling more laboratories to offer the clinically superior T-SPOT.TB test to more physicians, said Phill Keefe, chief executive officer of PerkinElmers Oxford Immunotec division.
  • This results in the highest quality of care for the most vulnerable patients across the United States.

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

Retrieved on: 
Thursday, September 22, 2022

CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.

Key Points: 
  • CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.
  • CDE's Breakthrough Therapy Designation is designed to expedite the clinical development of innovative drugs presenting significant clinical advantages.
  • [i] FDA granted CMG901 fast track designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.
  • Accessed September 12, 2022. https://prn.to/3jXET0G
    [ii] CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the orphan-drug designation by the Food and Drug Administration of the United States.

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

Retrieved on: 
Thursday, September 22, 2022

CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.

Key Points: 
  • CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.
  • CDE's Breakthrough Therapy Designation is designed to expedite the clinical development of innovative drugs presenting significant clinical advantages.
  • [i] FDA granted CMG901 fast track designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.
  • Accessed September 12, 2022. https://prn.to/3jXET0G
    [ii] CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the orphan-drug designation by the Food and Drug Administration of the United States.

CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit

Retrieved on: 
Wednesday, September 21, 2022

Of these 17 patients, five patients (29.4%) had extramedullary disease (EMD; 1 plasmacytoma) and nine patients (52.9%) had high-risk cytogenetic features.

Key Points: 
  • Of these 17 patients, five patients (29.4%) had extramedullary disease (EMD; 1 plasmacytoma) and nine patients (52.9%) had high-risk cytogenetic features.
  • Prior to zevor-cel infusion, patients received lymphodepletion regimen of fludarabine (30mg/m2 for three consecutive days) and cyclophosphamide (500mg/m2 for two consecutive days).
  • Zevor-cel (CT053) is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of R/R MM.
  • CARsgen is conducting a Phase 1b/2 clinical trial (LUMMICAR STUDY 2) in North America to evaluate the safety and efficacy of zevor-cel for R/R MM.